Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous stem cell transplantation versus chemotherapy alone in multiple myeloma
NL-OMON20547Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 1995
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, doxorubicin, dexamethasone, cyclophosphamide, melphalan and 1 more in multiple myeloma (MM) (3 arms), sponsored by HOVON. Primary endpoint: Remission rate. Started Nov 1995; status: active, not recruiting.
02
Drugs
vincristinedoxorubicindexamethasonecyclophosphamidemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON20547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20547.